Migraine sufferers in the UK may soon have access to a new drug, Atogepant, to help prevent their debilitating headaches. Recommended by NICE, Atogepant is designed specifically to block the CGRP protein, believed to contribute to migraine development, and has shown promising results in clinical trials.